Clinical Trial

Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial

Study acronym: ZGR in SBLPN
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
:The aim of this study was to analyze the safety and efficacy of Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma with Prominent Nucleoli (SBLPN). The main questions it aims to explore the Preliminary Efficacy of the Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) Regimen in the Treatment of Newly Diagnosed SBLPN Patients. To explore the safety of zanubrutinib, obinutuzumab combined with lenalidomide (ZGR) in the treatment of newly diagnosed SBLPN patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-03.
Status change: Not Yet Recruiting → Recruiting 2025-12-11
Trial Details
NCT Number NCT07165769
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN
Enrollment 47 participants
Start Date 2025-09-04
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-18